Semaglutide - Ozempic(R) is Chemically Stable When Administered Using NuGen's Needle Free InsuJet(TM) Device #Chemicals #HealthCare #Investing #Medical #NGMD.CA #NGMD.V #NuGenMD #Pharmaceutical #Pharmaceuticals #SmallCaps #TSXV

Toronto, Ontario--(Newsfile Corp. - October 10, 2023) - NuGen Medical Devices Inc. (TSXV: NGMD) (the "Company" or "NuGen") a leading developer of needle free devices to administer therapeutics subcutaneously, today presented new data from a preliminary trial that semaglutide (Ozempic®) is chemically stable after it is administered through NuGen's InsuJet™ needle-free injection device. "Today's discovery paves the way for future tests to validate the findings and prepare for the rigors of...


http://dlvr.it/SxH7G3

Comments

Popular posts from this blog

SEC Investor Advisory Committee to Discuss Exempt Offerings and Accredited Investors at September 21 Meeting #Banking #FinancialServices

ICEBERG Financial Announces New Fintech Product and Pre-Launch Institutional Contract #Banking #FinancialServices

Cleantek Industries Inc. Announces a Twelve-Month Extension of Credit Facility #CTEK.CA #CTEK.V #GLKFF #Investing #OTC #OTCMarkets #OTCStocks #SmallCaps #TSXV #Technology